Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) is the first and only PD-(L)1 inhibitor for subcutaneous (SC) injection for patients in the US, following FDA approval today. Tecentriq Hybreza can be injected subcutaneously over approximately seven minutes, compared with 30-60 minutes for standard IV infusion of atezolizumab. The SC formulation will be available for all IV indications of atezolizumab approved for adults in the US, including melanoma and certain other types of lung, liver, and soft tissue cancer.
Trial data showed comparable levels of atezolizumab in the blood when administered subcutaneously or via IV. The safety and efficacy profile of the SC formulation are consistent with the IV formulation.
Data also show that 71% of patients preferred Tecentriq Hybreza over intravenous atezolizumab. After experiencing both formulations, 4 out of 5 patients (79%) chose SC administration to continue their treatment.
The post Genetech’s Melanoma Drug Now Approved for Subcutaneous Delivery appeared first on Dermatology Education Foundation.